Gillian McGovern

1 week ago | pharmacytimes.com | Gillian McGovern

The FDA granted a fast track designation to INX-315 (Incyclix Bio, LLC) for the treatment of cyclin E1 (CCNE1)-amplified platinum-resistant or refractory ovarian cancer. Preclinical data demonstrated that in CCNE1-amplified cancer models, INX-315 was able to potently block Rb phosphorylation, arrest cells in the G1 phase of the cell cycle, and inhibit cell proliferation.

1 week ago | pharmacytimes.com | Gillian McGovern |Jennifer L. Guthrie

CommentaryArticleMay 4, 2025Author(s):,Jennifer Guthrie, RPh, district leader at CVS pharmacy describes the different medications to treat allergy symptoms and highlight how CVS stands out when addressing patients’ needs. In an interview with Pharmacy Times®, Jennifer Guthrie, RPh, district leader at CVS Pharmacy, discusses the 3 main OTC products for seasonal allergies: antihistamines, corticosteroids, and decongestants.

1 week ago | pharmacytimes.com | Gillian McGovern

Research findings published in hLife demonstrate an approach in which the proprietary ferritin nanoparticle-preS1 (ferritin-NP-preS1) therapeutic vaccine is synergistically combined with a preclinically validated hepatitis B virus (HBV)-specific small interfering RNA (siRNA), representing a significant advancement in a durable and functional cure of chronic hepatitis B (CHB).

1 week ago | pharmacytimes.com | Gillian McGovern

A single oral dose of baloxavir marboxil (Xofluza; Genentech, Roche) taken by patients with influenza reduced the odds of untreated household members contracting the virus by approximately 32%, according to research findings published in The New England Journal of Medicine.

1 week ago | pharmacytimes.com | Gillian McGovern

Investigators of research published in Biomaterials have developed a next-generation exosome-based drug delivery technology that is effective in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).